BMI1 and neoplasm: BMI1 specific inhibition pharmacologically or genetically was capable of eliminating CSC BMI1 + and leads to cellular immune activation against the tumor in addition to improvement of anti-PD-1 therapy, achieving inhibition of tumor growth, spread, and relapse.